Study of natural compounds target RANKL signaling pathway for treating bone diseases.
Millions of people, especially for the aging people, are suffered by bone-loss diseases, such as: rheumatoid arthritis and osteoporosis. Therefore, the better understanding for the involved mechanisms of bone metabolism is promising for treat such diseases. Particularly, during the pathological process of bone loss, RANKL as a member of the tumor necrosis factor (TNF) superfamily, could induce osteoclast precursor cells differentiation into mature osteoclasts, which further play a critical role in osteolysis. In recent years, with the growing attentions paid to the natural compounds researching studies, the therapeutic application of natural active plant derivatives has been widely recognized. Our present study summarized the current novel research progress of RANKL and its downstream signaling pathways in bone cells, and as an important drug targets for its role in bone loss diseases. Besides that, in our review, we briefly introduced the current application of several natural compounds for treating RANKL-mediated osteoclastic activation by modulating the RANKL signaling pathway and their effects on the treatment and prevention of osteoporosis, osteoarthritis and rheumatoid arthritis.